An extremely different dysmetabolic profile has been reported between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
MANFREDI, ROBERTO;CALZA, LEONARDO;CHIODO, FRANCESCO
2005
Abstract
An extremely different dysmetabolic profile has been reported between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
